![Frontiers | Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution Frontiers | Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution](https://www.frontiersin.org/files/MyHome%20Article%20Library/1067252/1067252_Thumb_400.jpg)
Frontiers | Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
![Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABAA receptor α2 subunit | Molecular Psychiatry Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABAA receptor α2 subunit | Molecular Psychiatry](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41380-022-01468-z/MediaObjects/41380_2022_1468_Fig1_HTML.png)
Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABAA receptor α2 subunit | Molecular Psychiatry
![Will the coronavirus ever stop mutating? Experts explain how Omicron and other variants emerge - The Boston Globe Will the coronavirus ever stop mutating? Experts explain how Omicron and other variants emerge - The Boston Globe](https://www.bostonglobe.com/resizer/zx2PfnHRgZ5wGgaIBhlfB8cIlFk=/arc-anglerfish-arc2-prod-bostonglobe/public/RSYPYBFAZI2FZUYOGICSRT23GA.jpg)
Will the coronavirus ever stop mutating? Experts explain how Omicron and other variants emerge - The Boston Globe
Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast C
Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
![Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab | GSK Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab | GSK](https://presentations.gsk.com/wp-content/uploads/2022/10/Dost63699_ESGO2022_GARNET-Mut-Meth_Figure-2.jpg)